Literature DB >> 28975595

Risk factors for non-alcoholic fatty liver disease are common in patients with non-B non-C hepatocellular carcinoma in India.

Deepu David1, Anantharam Raghavendran2, Ashish Goel3, C Bharath Kumar4, Thomas Alex Kodiatte5, Deepak Burad5, Priya Abraham2, Banumathi Ramakrishna5, Philip Joseph6, Jeyamani Ramachandran3, C E Eapen3.   

Abstract

AIM OF THE STUDY: The aim of the study was to analyze the prevalence of risk factors for non-alcoholic fatty liver disease (NAFLD) in patients with non-B non-C hepatocellular carcinoma (HCC).
METHODS: Between June 2012 and November 2014, patients with HCC, negative for hepatitis B surface antigen and hepatitis C virus antibody, were included in this study. All patients were assessed for risk factors for NAFLD such as diabetes mellitus (DM), hypertension, dyslipidemia, metabolic syndrome, and obesity.
RESULTS: Forty-seven patients with non-B non-C HCC (males, 37; age, 60±10 years; mean±SD) were studied. Model for end-stage liver disease score was 11±4. Twenty-five patients were in Child's class A. History of significant alcohol intake was noted in 11 (23%) patients. Prevalence of risk factors for NAFLD were obesity 24 (51%), DM 22 (47%), metabolic syndrome 21 (45%), hypertension 16 (34%), and dyslipidemia 13 (28%). Forty (85%) patients had at least one risk factor for NAFLD. The mean duration of at least one NAFLD risk factor was 7.5 years, prior to diagnosis of HCC. Thirteen (28%) patients were positive for anti-HBc; however, none of the study patients had detectable HBV DNA in blood.
CONCLUSIONS: Eighty-five percent of the patients with non-B non-C HCC had at least one risk factor for NAFLD. None of the study patients had occult hepatitis B infection. NAFLD is emerging as the major etiological contributing factor for non-B non-C HCC in India.

Entities:  

Keywords:  Hepatocellular carcinoma; NAFLD; Non-B non-C HCC; Occult hepatitis B

Mesh:

Year:  2017        PMID: 28975595     DOI: 10.1007/s12664-017-0785-x

Source DB:  PubMed          Journal:  Indian J Gastroenterol        ISSN: 0254-8860


  39 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

2.  Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

Authors:  Elisabetta Bugianesi; Nicola Leone; Ester Vanni; Giulio Marchesini; Franco Brunello; Patrizia Carucci; Alessandro Musso; Paolo De Paolis; Lorenzo Capussotti; Mauro Salizzoni; Mario Rizzetto
Journal:  Gastroenterology       Date:  2002-07       Impact factor: 22.682

3.  Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012.

Authors:  Bruce A Runyon
Journal:  Hepatology       Date:  2013-04       Impact factor: 17.425

4.  Features and outcome after liver resection for non-B non-C hepatocellular carcinoma.

Authors:  Kazuhisa Kaneda; Shoji Kubo; Hiromu Tanaka; Shigekazu Takemura; Kazuki Ohba; Takahiro Uenishi; Shintaro Kodai; Hiroji Shinkawa; Yorihisa Urata; Masayuki Sakae; Takatsugu Yamamoto; Shigefumi Suehiro
Journal:  Hepatogastroenterology       Date:  2012-09

5.  Profile of hepatocellular carcinoma in India: an insight into the possible etiologic associations.

Authors:  S K Sarin; V Thakur; R C Guptan; S Saigal; V Malhotra; S P Thyagarajan; B C Das
Journal:  J Gastroenterol Hepatol       Date:  2001-06       Impact factor: 4.029

6.  Hepatocellular carcinoma continues to be diagnosed in the advanced stage: profile of hepatocellular carcinoma in a tertiary care hospital in South India.

Authors:  Sandip Pal; Jeyamani Ramachandran; Reuben Thomas Kurien; Anu Eapen; Banumathi Ramakrishna; Shyamkumar N Keshava; Ashish Goel; K G Sajith; C E Eapen
Journal:  Trop Doct       Date:  2013-02-26       Impact factor: 0.731

7.  [The significance of anti-HBc and occult hepatitis B virus infection in the occurrence of hepatocellular carcinoma in patients with HBsAg and anti-HCV negative alcoholic cirrhosis].

Authors:  Min Ju Kim; Oh Sang Kwon; Nak So Chung; Seo Young Lee; Hyuk Sang Jung; Dong Kyun Park; Yang Suh Ku; Yu Kyung Kim; Yun Soo Kim; Ju Hyun Kim
Journal:  Korean J Hepatol       Date:  2008-03

8.  Prevalence of occult hepatitis B virus infection among hepatopathy patients and healthy people in China.

Authors:  Yong Fang; Qing-Long Shang; Jian-Yu Liu; Di Li; Wei-Zhen Xu; Xu Teng; Hong-Wei Zhao; Li-Juan Fu; Feng-Min Zhang; Hong-Xi Gu
Journal:  J Infect       Date:  2009-03-29       Impact factor: 6.072

9.  Prevalence of genotype D in chronic liver disease patients with occult HBV infection in northern region of India.

Authors:  Meher Rizvi; Mohd Azam; Asfia Sultan; Indu Shukla; Abida Malik; Masihur Reman Ajmal; Fatima Khan; Hiba Sami
Journal:  Indian J Pathol Microbiol       Date:  2014 Oct-Dec       Impact factor: 0.740

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  6 in total

Review 1.  2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations.

Authors:  Ashish Kumar; Subrat K Acharya; Shivaram P Singh; Anil Arora; Radha K Dhiman; Rakesh Aggarwal; Anil C Anand; Prashant Bhangui; Yogesh K Chawla; Siddhartha Datta Gupta; Vinod K Dixit; Ajay Duseja; Naveen Kalra; Premashish Kar; Suyash S Kulkarni; Rakesh Kumar; Manoj Kumar; Ram Madhavan; V G Mohan Prasad; Amar Mukund; Aabha Nagral; Dipanjan Panda; Shashi B Paul; Padaki N Rao; Mohamed Rela; Manoj K Sahu; Vivek A Saraswat; Samir R Shah; Praveen Sharma; Sunil Taneja; Manav Wadhawan
Journal:  J Clin Exp Hepatol       Date:  2019-09-23

2.  Prevalence of Risk Factors for Nonalcoholic Fatty Liver Disease in Middle-Aged and Elderly Patients With Cryptogenic Cirrhosis.

Authors:  Chandrashekaraiah Bharath Kumar; Ashish Goel; Rajeeb Jaleel; Deepu David; Uday Zachariah; Jeyamani Ramachandran; Chundamannil E Eapen
Journal:  J Clin Exp Hepatol       Date:  2021-06-16

Review 3.  What Are the Current Pharmacological Therapies for Nonalcoholic Fatty Liver Disease?

Authors:  Deepu David; Chundamannil E Eapen
Journal:  J Clin Exp Hepatol       Date:  2020-09-03

4.  Profile of patients with hepatocellular carcinoma: An experience from a tertiary care center in India.

Authors:  Balaji Musunuri; Shiran Shetty; Ganesh Bhat; Karthik Udupa; Ananth Pai
Journal:  Indian J Gastroenterol       Date:  2022-02-28

Review 5.  MAFLD enhances clinical practice for liver disease in the Asia-Pacific region.

Authors:  Takumi Kawaguchi; Tsubasa Tsutsumi; Dan Nakano; Mohammed Eslam; Jacob George; Takuji Torimura
Journal:  Clin Mol Hepatol       Date:  2021-11-10

6.  First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study.

Authors:  Shigeo Shimose; Atsushi Hiraoka; Masahito Nakano; Hideki Iwamoto; Masatoshi Tanaka; Takaaki Tanaka; Kazunori Noguchi; Hajime Aino; Kei Ogata; Masahiko Kajiwara; Satoshi Itano; Yoshinori Yokokura; Taizo Yamaguchi; Hiroshi Kawano; Norito Matsukuma; Hideya Suga; Takashi Niizeki; Tomotake Shirono; Yu Noda; Naoki Kamachi; Shusuke Okamura; Takumi Kawaguchi; Hironori Koga; Takuji Torimura
Journal:  Cancer Med       Date:  2021-10-24       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.